# Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers

> **NCT07252726** · PHASE4 · RECRUITING · sponsor: **Ottawa Hospital Research Institute** · enrollment: 50 (estimated)

## Conditions studied

- Metastatic Breast Cancer
- Metastatic Prostate Cancer

## Interventions

- **OTHER:** Morning administration of CDK4/6 inhibitor
- **OTHER:** Evening administration of CDK4/6 inhibitor
- **OTHER:** Morning administration of ARPI
- **OTHER:** Evening administration of ARPI

## Key facts

- **NCT ID:** NCT07252726
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-02
- **Primary completion:** 2027-03
- **Final completion:** 2033-03
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07252726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07252726, "Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT07252726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*